Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases
Volume 8, Issue 2, Pages 89-94
http://dx.doi.org/10.1155/1997/973029
Original Article

Prospective, Randomized Comparison of Intravenous and Oral Ciprofloxacin with Intravenous Ceftazidime in the Treatment of Nosocomial Pneumonia

Raphael Saginur,1,3 Gary Garber,3 Gail Darling,4 Stephen Shafran,5,6 William Cameron,2 Gwynne Jones,2 Francois Auclair,3 and the Canadian Infectious Disease Society Multicenter Nosocomial Pneumonia Study Group

1Department of Medicine, Ottawa Civic Hospital, Canada
2Department of Medicine, Ottawa General Hospital, Canada
3University of Ottawa, Ottawa, Ontario, Canada
4Department of Surgery, Wellesley Hospital and University of Toronto, Toronto, Ontario, Canada
5Department of Medicine, University of Alberta Hospitals, Canada
6University of Alberta, Edmonton, Alberta, Canada

Received 12 January 1996; Accepted 2 September 1996

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

OBJECTIVE: To compare the efficacy of intravenous and oral ciprofloxacin and intravenous ceftazidime in the treatment of nosocomial pneumonia.

DESIGN: Randomized, nonblinded, multicentre comparative trial.

SETTING: Seven Canadian university hospitals.

POPULATION: Adult patients with moderate to severe pneumonia developing 72 h or longer after hospitalization.

METHODS: After informed consent was obtained, patients were randomized to receive intravenous ciprofloxacin 300 mg every 12 h or ceftazidime 2 g every 8 h. After three days, patients in the ciprofloxacin arm could be switched to oral ciprofloxacin, 750 mg every 12 h. Concomitant clindamycin was allowed for three days in patients with syndromes consistent with Gram-positive or anaerobic infection. Erythromycin could be used if cultures revealed no pathogen.

RESULTS: A total of 149 patients were enrolled, of whom 124 were eligible for efficacy analysis. Of 119 pathogens identified in 87 patients, 84 were Gram-negative, and 35 Gram-positive. The mean duration of ciprofloxacin therapy was 12.1 days, of which 9.2 days were given intravenously. Ceftazidime was given for a mean of 9.8 days. There was eradication or reduction of pathogens in 75.7% of ciprofloxacin patients and 70.6% of the ceftazidime group. Clinical resolution or improvement occurred in 87.1% of ciprofloxacin recipients and 87.3% of the ceftazidime group. Eight ciprofloxacin and six ceftazidime patients died. Overall outcomes were considered to be successful in 85.2% of ciprofloxacin patients and 87.1% of ceftazidime recipients. Adverse events were mild.

CONCLUSIONS: There were similar efficacy and safety of intravenous and oral ciprofloxacin and intravenous ceftazidime in the treatment of patients with hospital-acquired pneumonia. Physicians were reluctant to use oral therapy in patients.